<< Topic

No Link Between IBD Treatment and Cancer Risk

By Staff


US Pharm. 2014;39(7):6.

Copenhagen, Denmark— In a study of more than 56,000 patients with inflammatory bowel disease (IBD), the use of tumor necrosis factor-alpha (TNF-alpha) antagonists was not associated with a greater risk of cancer. Using records from the National Patient Registry of Denmark, investigators at the Statens Serum Institut studied cancer rates in IBD patients aged ≥15 years, 8% of whom were treated with TNF-alpha antagonists. In a median follow-up of 3.7 years, cancer developed in nearly 7% of patients not exposed to TNF-alpha antagonists and in nearly 2% of those treated with TNF-alpha antagonists. No site-specific cancers were found in significant excess. However, an increased risk of malignancy in the long term cannot be excluded, the investigators cautioned.

To comment on this article, contact
Popular Articles